MedTrace Logo

GnRH Agonist and Intrauterine Insemination

NCT00503217 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2016-09-07

No results posted yet for this study

Summary

The aim of this study is to assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles.

Conditions

  • Intrauterine Insemination

Interventions

DRUG

Tryptorelin

Sponsors & Collaborators

  • Instituto Valenciano de Infertilidad, IVI VALENCIA

    lead OTHER

Principal Investigators

  • Jose Bellver, MD · Instituto Valenciano de la Infertilidad

  • Elena Labarta, MD · Instituto Valenciano de Infertilidad

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00503217 on ClinicalTrials.gov